merit medical systems, inc. (nasdaq: mmsi) is a leading manufacturer of medical devices used in diagnostic & interventional cardiology & radiology procedures. its primary products consist of inflation devices used in angioplasty, stent placement & discography; diagnostic & therapeutic catheters used for various procedures in cardiology & radiology; guide wires used to place balloon angioplasty catheters within a patient's coronary arteries; products used to manage & monitor the administration of contrast & other fluid solutions during diagnostic & therapeutic procedures; thrombolytic catheters & fluid dispensing systems; angiography accessories; & standard & custom angiography kits. headquartered in south jordan, utah, a suburb of salt lake city, merit employs approximately 1,900 people worldwide. merit markets its products in the united states & europe (direct sales force) & the world (distributors). they call directly on physicians & clinicians in hospitals & clinics worldwide. the c
Company profile
Ticker
MMSI
Exchange
Website
CEO
Fred Lampropoulos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Merit Medical Australia Pty Ltd. • ITL Healthcare Pty Ltd. • Merit Medical Austria GmbH • Merit Medical Canada Ltd. • Merit Medical Colombia S.A.S. • Merit Medical Beijing Co. Ltd. • BioSphere Medical Japan, Inc. • BioSphere Medical, Inc. • Brightwater Medical, Inc. • BSMD Ventures, Inc. ...
IRS number
870447695
MMSI stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
2 Apr 24
DEFA14A
Additional proxy soliciting materials
2 Apr 24
DEF 14A
Definitive proxy
2 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Results of Operations and Financial Condition
28 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Dec 23
8-K
Regulation FD Disclosure
6 Dec 23
8-K
Regulation FD Disclosure
4 Dec 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
Transcripts
MMSI
Earnings call transcript
2023 Q3
26 Oct 23
MMSI
Earnings call transcript
2023 Q2
25 Jul 23
MMSI
Earnings call transcript
2023 Q1
26 Apr 23
MMSI
Earnings call transcript
2022 Q4
22 Feb 23
MMSI
Earnings call transcript
2022 Q3
27 Oct 22
MMSI
Earnings call transcript
2022 Q2
28 Jul 22
MMSI
Earnings call transcript
2022 Q1
28 Apr 22
MMSI
Earnings call transcript
2021 Q4
26 Feb 22
MMSI
Earnings call transcript
2021 Q4
24 Feb 22
MMSI
Earnings call transcript
2021 Q3
29 Oct 21
Latest ownership filings
4
Brian G. Lloyd
15 Mar 24
4
Raul Jr. Parra
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
Joseph Wright
8 Mar 24
4
Neil Peterson
8 Mar 24
4
Michel James Voigt
6 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
4
Neil Peterson
6 Mar 24
4
Joseph Wright
6 Mar 24
4
Brian G. Lloyd
6 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 60.73 mm | 60.73 mm | 60.73 mm | 60.73 mm | 60.73 mm | 60.73 mm |
Cash burn (monthly) | 4.47 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 30.90 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 29.83 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 6.7 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
95.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 270 |
Opened positions | 27 |
Closed positions | 66 |
Increased positions | 100 |
Reduced positions | 113 |
13F shares | Current |
---|---|
Total value | 3.79 tn |
Total shares | 55.15 mm |
Total puts | 2.40 k |
Total calls | 25.00 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 9.97 mm | $688.02 bn |
Vanguard | 7.02 mm | $484.18 bn |
William Blair Investment Management | 3.90 mm | $268.88 bn |
Conestoga Capital Advisors | 2.14 mm | $147.70 bn |
STT State Street | 2.10 mm | $145.21 bn |
ArrowMark Colorado | 1.57 mm | $108.05 bn |
Fuller & Thaler Asset Management | 1.39 mm | $95.86 bn |
MCQEF Macquarie | 1.29 mm | $88.84 bn |
Dimensional Fund Advisors | 1.27 mm | $87.36 bn |
Geode Capital Management | 1.19 mm | $82.42 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Brian G. Lloyd | Common Stock, No Par Value | Gift | Dispose G | No | No | 0 | 1,180 | 0.00 | 24,602 |
12 Mar 24 | Raul Jr. Parra | Common Stock, No Par Value | Sell | Dispose S | No | No | 73.92 | 6,179 | 456.75 k | 12,007 |
12 Mar 24 | Raul Jr. Parra | Common Stock, No Par Value | Sell | Dispose S | No | No | 74.52 | 301 | 22.43 k | 18,186 |
7 Mar 24 | Joseph Wright | Common Stock, No Par Value | Sell | Dispose S | No | No | 75.677 | 25,000 | 1.89 mm | 42,223 |
7 Mar 24 | Joseph Wright | Common Stock, No Par Value | Option exercise | Acquire M | No | No | 28.2 | 25,000 | 705.00 k | 67,223 |
7 Mar 24 | Joseph Wright | NQSO Common Stock | Option exercise | Dispose M | No | No | 28.2 | 25,000 | 705.00 k | 0 |
6 Mar 24 | Neil Peterson | Common Stock, No Par Value | Option exercise | Acquire M | No | No | 44.8 | 7,500 | 336.00 k | 14,819 |
6 Mar 24 | Neil Peterson | NQSO Common Stock | Option exercise | Dispose M | No | No | 44.8 | 7,500 | 336.00 k | 7,500 |
4 Mar 24 | Stephen C. Evans | Common Stock, No Par Value | Sell | Dispose S | No | No | 76.348 | 1,000 | 76.35 k | 7,226 |
News
Barrington Research Maintains Outperform on Merit Medical Systems, Maintains $98 Price Target
16 Apr 24
CL King Initiates Coverage On Merit Medical Systems with Buy Rating, Announces Price Target of $88
11 Apr 24
Decoding 7 Analyst Evaluations For Merit Medical Systems
11 Apr 24
Needham Reiterates Buy on Merit Medical Systems, Maintains $88 Price Target
11 Apr 24
Merit Medical Launches The FDA Cleared Micro ACE Advanced Micro-Access System
19 Mar 24